Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). In the case of drug-related grade ≥3 or selected prolonged grade 2 adverse events (AEs), the dose can be reduced by 10 mg decrements to a minimum of 20 mg. Here, we evaluate the influence of afatinib dose reduction on AEs, pharmacokinetics and progression-free survival (PFS) in the phase III LUX-Lung 3 and 6 (LL3/6) trials. PATIENTS AND METHODS: Treatment-naïve patients with advanced EGFR mutation-positive NSCLC in LL3 (global) and LL6 (China, Thailand, South Korea) were randomized to afatinib or chemotherapy. All afatinib-treated patients (LL3, n = 229; LL6, n = 239) were included in the post hoc analyses. Incidence and severity of common AEs before and after afatinib dose reduction were assessed. Afatinib plasma concentrations were compared in patients who reduced to 30 mg versus those remaining at 40 mg. PFS was compared between patients who dose reduced within the first 6 months of treatment and those who did not. RESULTS: Dose reductions occurred in 53.3% (122/229) and 28.0% (67/239) of patients in LL3 and LL6, respectively; most (86.1% and 82.1%) within the first 6 months of treatment. Dose reduction led to decreases in the incidence of drug-related AEs, and was more likely in patients with higher afatinib plasma concentrations. On day 43, patients who dose reduced to 30 mg (n = 59) had geometric mean afatinib plasma concentrations of 23.3 ng/ml, versus 22.8 ng/ml in patients who remained on 40 mg (n = 284). The median PFS was similar in patients who dose reduced during the first 6 months versus those who did not {LL3: 11.3 versus 11.0 months [hazard ratio (HR) 1.25]; LL6: 12.3 versus 11.0 months (HR 1.00)}. CONCLUSIONS: Tolerability-guided dose adjustment is an effective measure to reduce afatinib-related AEs without affecting therapeutic efficacy. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifiers: NCT00949650 and NCT0112393.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“afatinib dose reductions in the LUX-Lung 3 and 6 trials (in line with the criteria described above) resulted in a major reduction in treatment-related grade ≥3 AEs (from 73.0% to 20.5% in LUX-Lung 3 and from 80.6% to 11.9% in LUX-Lung 6) without affecting therapeutic efficacy, as assessed by PFS.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Self-citationZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationWu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Self-citationYang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Self-citationPark, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
Self-citationSolca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
Research works printed but not linked: 1
- Yang, 2013, Epidermal growth factor receptor (EGFR)-mediated adverse events in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) treated with afatinib, Eur J Cancer, 49, 895
Cited by
Overview of current systemic management of EGFR-mutant NSCLC
Hsu, W.-H., Yang, J. C.-H., Mok, T. S., & Loong, H. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx702 · Cited by 388
Self-citationNan, X., Xie, C., Yu, X., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20095 · Cited by 190
“A combination analysis of LUX-lung3 and LUXlung6 [13, 25] had proved that 19 exon deletion tumours were different from L858R mutations tumours, and the former may be better: median OS was better in the 19 exon deletion compared with the chemotherapy group no matter in LUX-Lung 3 or LUX-Lung 6, while no statistically s…”
MethodShah, R., & Lester, J. F. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.003 · Cited by 174
Self-citationEGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 139
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115
“…(cid:4) 3 AEs (from 73.0% to 20.5% in LUX-Lung 3 and from 80.6% to 11.9% in LUX-Lung 6) without affecting therapeutic efficacy, as assessed by PFS. 88 Furthermore, in a noninterventional, observational study conducted in a real-world setting, dose reductions with afatinib were shown to reduce the…”
BackgroundInfluential
Metadata
- Authors
- Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., Lu, S., Hirsh, V., Huang, Y., Sebastian, M., Okamoto, I., Dickgreber, N., Shah, R., Märten, A., Massey, D., Wind, S., & Wu, Y.-L.
- Affiliations
- National Taiwan University Hospital (TW)
- Harvard University (US)
- Tongji University (CN)
- Prince of Songkla University (TH)
- Chinese University of Hong Kong (HK)
- Xiangya Hospital Central South University (CN)
- Wakayama Medical University (JP)
- Jiangsu Cancer Hospital (CN)
- Queensland University of Technology (AU)
- McGill University (CA)
- Kunming Medical University (CN)
- Goethe University Frankfurt (DE)
- Kyushu University (JP)
- Klinikum Rheine (DE)
- Maidstone Hospital (GB)
- Boehringer Ingelheim (Germany) (DE)
- Guangdong General Hospital (CN)
- Corresponding author
- Wu, Y.-L.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 27
- Issue
- 11
- Pages
- 2103-2110
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2512922897
- Cited by
- 194
- References
- 24
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 9 · 2023: 13 · 2022: 15 · 2021: 34 · 2020: 21 · 2019: 34 · 2018: 24 · 2017: 21 · 2016: 1
- FWCI
- 23.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1099 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, EGFR-mutant non-small cell lung cancer, lung adenocarcinoma, dose reduction, dose adjustment, adverse events, pharmacokinetics, plasma drug concentration, progression-free survival, first-line therapy, tyrosine kinase inhibitors, tolerability, efficacy, Chinese patients, Thai patients, South Korean patients
- MeSH terms
- Adenocarcinoma of Lung, Afatinib, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, China, Dose-Response Relationship, Drug, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Disease-Free Survival, Protein Kinase Inhibitors, Republic of Korea, Drug-Related Side Effects and Adverse Reactions, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. https://app.cochat.ai/papers/10.1093/annonc/mdw322
- The paper
- Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., Lu, S., Hirsh, V., Huang, Y., Sebastian, M., Okamoto, I., Dickgreber, N., Shah, R., Märten, A., Massey, D., . . . Wu, Y.-L. (2016). Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Annals of Oncology. https://doi.org/10.1093/annonc/mdw322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.